Nebivolol had similar benefits irrespective of baseline SBP : the hazard ratio ( HR ) for primary outcome of all-cause mortality or cardiovascular hospitalization in the three SBP categories for nebivolol vs. placebo was 0.85 [ 95 % confidence interval ( CI ) 0.50-1 .45 ] , 0.79 ( 95 % CI 0.61-1 .01 ) , and 0.88 ( 95 % CI 0.72-1 .07 ) , respectively ( P for interaction = 0.61 ) .